Skip to main content
Clinical Trials/DRKS00016731
DRKS00016731
Completed
Not Applicable

Predictive value of ultrasonographic parameters fortherapy response in Crohn’s disease and ulcerativecolitis patients - TRUST BEYOND

AbbVie Deutschland GmbH & Co. KG0 sites246 target enrollmentMay 29, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
K50
Sponsor
AbbVie Deutschland GmbH & Co. KG
Enrollment
246
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 29, 2019
End Date
March 31, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • \- Patients \= 18 years
  • \- CD: Patients with a proven diagnosis of Crohn’s disease or ulcerative colitis, and moderate to severe disease activity who have been selected for start of TIM therapy.
  • \- Patients with increased bowel wall thickness (BWT) at baseline

Exclusion Criteria

  • \- Patients post bowel resection surgery, patients with ileal stoma or ileoanal pouch
  • \- CD patients with disease restricted to small bowel other than terminal ileum, gastroduodenal or anorectal areas
  • \- UC patients having disease limited to the rectum (ulcerative proctitis)
  • \- Patients with therapy failure to more than 2 prior biologics/JAK\-therapy
  • \- Patients who cannot be examined by ultrasound
  • \- Pregnant at study start
  • \- Infectious colitis (e.g. Cytomegalovirus (CMV), Clostridium Difficile (C.diff)
  • \- Preparation of endoscopy at day of Gastrointestinal Ultrasound (GIUS) assessment or on the day before

Outcomes

Primary Outcomes

Not specified

Similar Trials